Adam is responsible for management of all medical/life science out-licensing and new venture formation activities at Isis Innovation Ltd, the technology transfer company of the University of Oxford. He has worked for more than a decade in the pharma/biotech sector in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management.

Between 2010 and 2013 Adam worked as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, which conducted the first ever efficacy study of a next generation TB vaccine in infants.

Prior to this Adam worked in consulting with Technomark Ltd and then in increasingly senior commercialisation roles at Isis.